下一代疗法比拼升级Infigratinib并非唯一挑战Vosoritide的选手，在ACH治疗赛道，多款下一代疗法正加速推进，从周剂注射到高选择性靶向，行业的研发比拼正不断升级，Vosoritide的垄断时代已进入倒计时。
Author(s): Yoshiyasu Takefuji
。WPS官方版本下载对此有专业解读
Galaxy S26 and S26+ Sam Rutherford for Engadget
Elise, 21, from Chester, has been to two concerts at Co-op Live, and is going to a third later this year.